JP2023175819A5 - - Google Patents

Info

Publication number
JP2023175819A5
JP2023175819A5 JP2023149578A JP2023149578A JP2023175819A5 JP 2023175819 A5 JP2023175819 A5 JP 2023175819A5 JP 2023149578 A JP2023149578 A JP 2023149578A JP 2023149578 A JP2023149578 A JP 2023149578A JP 2023175819 A5 JP2023175819 A5 JP 2023175819A5
Authority
JP
Japan
Prior art keywords
regnase
positions
phosphorylation
seq
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023149578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023175819A (ja
Filing date
Publication date
Priority claimed from JP2020523181A external-priority patent/JP7778301B2/ja
Application filed filed Critical
Publication of JP2023175819A publication Critical patent/JP2023175819A/ja
Publication of JP2023175819A5 publication Critical patent/JP2023175819A5/ja
Pending legal-status Critical Current

Links

JP2023149578A 2018-06-06 2023-09-14 Regnase-1が関与する疾患の治療および/または予防方法 Pending JP2023175819A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP2018108400 2018-06-06
JP2018108400 2018-06-06
JP2018167326 2018-09-06
JP2018167326 2018-09-06
JP2018229845 2018-12-07
JP2018229845 2018-12-07
JP2019089270 2019-05-09
JP2019089270 2019-05-09
JP2020523181A JP7778301B2 (ja) 2018-06-06 2019-06-06 Regnase-1が関与する疾患の治療および/または予防方法
PCT/JP2019/022582 WO2019235581A1 (ja) 2018-06-06 2019-06-06 Regnase-1が関与する疾患の治療および/または予防方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020523181A Division JP7778301B2 (ja) 2018-06-06 2019-06-06 Regnase-1が関与する疾患の治療および/または予防方法

Publications (2)

Publication Number Publication Date
JP2023175819A JP2023175819A (ja) 2023-12-12
JP2023175819A5 true JP2023175819A5 (https=) 2026-02-05

Family

ID=68769816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020523181A Active JP7778301B2 (ja) 2018-06-06 2019-06-06 Regnase-1が関与する疾患の治療および/または予防方法
JP2023149578A Pending JP2023175819A (ja) 2018-06-06 2023-09-14 Regnase-1が関与する疾患の治療および/または予防方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020523181A Active JP7778301B2 (ja) 2018-06-06 2019-06-06 Regnase-1が関与する疾患の治療および/または予防方法

Country Status (4)

Country Link
US (2) US20220125891A1 (https=)
EP (1) EP3804759A4 (https=)
JP (2) JP7778301B2 (https=)
WO (1) WO2019235581A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US20230029594A1 (en) * 2019-12-24 2023-02-02 Osaka University Body fat reducing agent and method for screening for substance capable of reducing body fat
CN116322716A (zh) 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
KR102560134B1 (ko) * 2021-04-01 2023-07-27 가톨릭대학교 산학협력단 세포투과성 Regnase-1 재조합 단백질 및 이를 유효성분으로 함유하는 항염증용 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
DE69222303T2 (de) 1991-04-30 1998-01-22 Eukarion Inc Kationisierte antikörper gegen intrazelluläre eiweisse
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
WO2007075845A2 (en) * 2005-12-20 2007-07-05 University Of Central Florida Research Foundation Isolated mcpip and methods of use
US20130195882A1 (en) * 2012-01-31 2013-08-01 Pappachan Kolattukudy Mcpip protection against osteoclast production
EP2141175B1 (en) * 2007-03-26 2016-07-27 The University of Tokyo Process for synthesizing cyclic peptide compound
WO2010098429A1 (ja) 2009-02-27 2010-09-02 国立大学法人大阪大学 免疫アジュバント組成物、及びその利用
JP5818237B2 (ja) 2010-09-09 2015-11-18 国立大学法人 東京大学 N−メチルアミノ酸およびその他の特殊アミノ酸を含む特殊ペプチド化合物ライブラリーの翻訳構築と活性種探索法
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
CN111437395A (zh) 2013-08-29 2020-07-24 希望之城 细胞穿透缀合物及其使用方法
WO2016013870A1 (ko) 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
DK3269809T3 (da) * 2015-03-13 2022-09-12 Chugai Pharmaceutical Co Ltd MODIFICERET AMINOACYL-tRNA-SYNTETASE OG ANVENDELSE DERAF
CN111093678A (zh) * 2017-07-21 2020-05-01 克利夫兰诊所基金会 用于治疗IL-17a相关疾病和病状的SBE适体
US11179412B2 (en) * 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
JP7258362B2 (ja) * 2018-03-22 2023-04-17 国立大学法人京都大学 炎症抑制用の組成物
WO2020032160A1 (ja) * 2018-08-09 2020-02-13 国立大学法人大阪大学 炎症性腸疾患治療薬およびそのスクリーニング方法

Similar Documents

Publication Publication Date Title
JP2023175819A5 (https=)
Lockhart et al. Tools for detecting a “superbug”: updates on Candida auris testing
Zapatka et al. The landscape of viral associations in human cancers
van Diepeningen et al. Diagnosis of Fusarium infections: approaches to identification by the clinical mycology laboratory
Pfarr et al. High‐throughput diagnostic profiling of clinically actionable gene fusions in lung cancer
McDonald et al. Pneumocystis jirovecii pneumonia in people living with HIV: a review
Sellarés et al. Molecular diagnosis of antibody‐mediated rejection in human kidney transplants
Javaugue et al. RNA-based immunoglobulin repertoire sequencing is a new tool for the management of monoclonal gammopathy of renal (kidney) significance
JP2012508865A5 (https=)
JP2017503473A5 (https=)
CA2673296A1 (en) Improved assay for immunosuppressant drugs
JP2006502416A5 (https=)
JP2008509673A5 (https=)
KR20090056781A (ko) 결핵균 및 비결핵 미코박테륨의 뉴클레오티드 증폭 산물을검출하기 위한 스트립 및 방법
Dong et al. Rapid evolutionary dynamics in a 2.8‐Mb chromosomal region containing multiple prolamin and resistance gene families in Aegilops tauschii
WO2014079002A1 (zh) Dna二代测序技术中待测样品的追踪方法及检测试剂盒
Royer et al. Comparison of metagenomic and traditional methods for diagnosis of E. coli enteric infections
Katz-Greenberg et al. Post-transplant lymphoproliferative disorders (PTLD)-from clinical to metabolic profiles-a single center experience and review of literature
CN102435748B (zh) 一种双抗夹心酶联免疫检测试剂盒及其制备方法
CN103288963B (zh) 吉他霉素残留检测用单克隆抗体及制备方法和应用
Tanca et al. High throughput genomic and proteomic technologies in the fight against infectious diseases
Tsukamoto et al. Lung pathology of mutually exclusive co-infection with SARS-CoV-2 and Streptococcus pneumoniae
KR20090131468A (ko) 노로바이러스 검출을 위한 프라이머 및 상기 프라이머를포함하는 노로바이러스 유전자 검출 및 유전자형 동정방법
Ohori et al. Immunological and morphological properties of HBeAg subtypes (HBeAg/1 and HBeAg/2) in hepatitis B virus core particles
Evangelou et al. SARS-CoV-2 infects lung epithelial cells and induces senescence and an inflammatory response in patients with severe COVID-19